Forecasting Clinical Ops Metrics
Posted on February 3rd, 2012 by mat
Next week we will be attending the SCOPE conference in Miami. Primarily serving clients in clinical operations in pharma and biotech companies, the conference is concerned with improving metrics, forecasts and management of clinical trials.
Building on our success with Genentech, we are looking forward to learning more about this opportunity and how Crowdcast can help bring drugs to market more efficiently.
Did you know:
- The average drug costs over $1B to get to market?
- Every day of delay costs approx $1.4MM (assumes $500MM revenue per year)?
- Only 6% of clinical trials are completed on time, and 72% of trials run over schedule by more than one month?
- Clinical trials last 42% longer than expected in Phase I, 31% longer in Phase II, and 30% beyond planned deadlines in Phase III – all because of recruitment delays?
If pharma companies could accurately assess and manage their clinical trials, especially around enrollment of patients, we assume that they could deliver their drugs to market faster and significantly increase profits.
The problems they face are myriad. They work with many sites (clinics, hospitals etc) with few patients per site. The trials are often international with varying regulations. Much of the work is outsourced to CROs, making a direct line of site with the clinic harder. In addition, the conditions change with alternative trials overlapping and competing for the limited number of potential patients required. Finally, the leader of the project and the CROs may have reason to be optimistic to ensure funding and selection of their particular site.
What they need is a way to aggregate accurate, real time forecasts, from a diverse set of players and reward for accuracy and insight :)




